NCT04145440 - Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

January 19, 2022

Study Completion Date

August 2, 2022

Conditions

Glomerulonephritis, MembranousantiPLA2R Positive

Interventions

DRUG

MOR202

Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

Trial Locations (45)

1020

C.H.U. Brugmann - Site Victor Horta, Brussels

1090

Universitair Ziekenhuis Brussels, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

2217

St. George Hospital, Sydney

3000

UZ Leuven, Leuven

3021

Western Health, Melbourne

3050

Royal Melbourne Hospital, Melbourne

4000

CHU de Liège, Liège

8035

Hospital Universitari Vall d'Hebron, Barcelona

9300

O.L.V. Ziekenhuis, Aalst

20132

Ospedale San Raffaele, Milan

28041

Hospital Universitario 12 de Octubre, Madrid

28222

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

30046

GA Nephrology Associates, Lawrenceville

33000

Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux

33136

University of Miami Division of Nephrology & Hypertension, Miami

35015

Chungnam National University Hospital, Daejeon

37124

Ospedale Borgo Roma, Verona

38043

CHU de Grenoble - Hôpital Albert Michallon, Grenoble

41013

Hospital Universitario Virgen del Rocio, Seville

42055

CHU Saint Etienne - Hôpital Nord, Saint-Priest-en-Jarez

43210

The Ohio State University Wexner Medical Center, Columbus

46014

Hospital General Universitario de Valencia, Valencia

46017

Hospital Universitario Dr. Peset, Valencia

50134

Azienda Ospedaliera Universitaria Careggi, Florence

Hospital Universitario Reina Sofia, Córdoba

55902

Mayo Clinic, Rochester

59037

Hopital Claude Huriez -CHU Lille, Lille

71101

Northwest Louisiana Nephrology Research, Shreveport

75020

Hopital Tenon Service de nephrologie, Paris

76248

Texas Research Institute, Fort Worth

79905

MedResearch, Inc, El Paso

90502

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

91702

North America Research Institute, Azusa

92213

SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz

94143

UCSF Medical Center, San Francisco

01107

Kidney Care and Transplant Services of New England, PC, Springfield

6525 GA

Radboud UMC Niimegen Nephrology, Nijmegen

00631

Centrum Zdrowia MDM, Warsaw

04749

Miedzyleski Szpital Specjalistyczny, Warsaw

05355

Hallym University Kangdong Sacred Heart Hospital, Seoul

06273

Gangnam Severance Hospital, Seoul

06591

The Catholic University of Korea, Seoul

Unknown

Severance Hospital, Yonsei University Health System, Seoul

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors

lead

HI-Bio, A Biogen Company

INDUSTRY